The TEL (for "translocation-ETS-leukemia," also referred to as ETV6) transcription factor is a target for disruption by chromosomal translocations in several forms of acute leukemia (24-27, 38, 50, 51, 54, 57, 63) . TEL was originally identified as the gene on chromosome 12 that is disrupted by t(5;12) in patients with chronic myelomonocytic leukemia (25) . This translocation fuses the N-terminal homodimerization domain of TEL to the tyrosine kinase domain of the platelet-derived growth factor receptor ␤. The N terminus of TEL is also fused to the majority of the AML-1B (Runx-1) transcription factor by t (12;21) , which is the most frequent translocation in pediatric B-cell acute lymphoblastic leukemias (23, 26, 57, 61) .
TEL is a member of the ETS family of transcription factors. ETS factors bind heterogenous sequences centered around a core GGA sequence and cooperate with other transcription factors to regulate the transcription of a diverse set of genes (28, 52, 74) . Several ETS factors are downstream effectors of oncogenic Ras proteins and are phosphorylated by mitogenactivated protein kinases (73, 80) . Aberrant expression of these ETS factors induces cellular transformation (73, 74) . By contrast, TEL acts as a transcriptional repressor. In t(12;21), fusion of the TEL N-terminal domain to AML-1 creates a dominant transcriptional repressor (18, 19, 32) . This observation led to the identification of an association between TEL and the mSin3A and SMRT corepressors (13, 20) .
The TEL gene maps to chromosome 12 region p13. Loss of heterozygosity in this region of chromosome 12 is found in many types of cancer including leukemias and tumors of the breast and ovary (25, 31, 58, 62, 66, 79) . For example, in more than 90% of cases associated with t(12;21), the second TEL allele also is deleted (26, 54, 57, 63) . These findings suggest that the widely expressed TEL protein may function as a tumor suppressor (12, 54, 64) . However, there is no direct evidence to support this hypothesis, because targeted disruption of the TEL gene in mice is lethal in utero at embryonic day 10.5 (E10.5) (71) . TEL knockout mice die of an inability to maintain the developing vascular network in the yolk sac (71) . However, hematopoietic progenitors from these embryos are capable of differentiating along the various blood cell lineages in vitro (71) . Therefore, TEL is not intrinsically required for the growth or differentiation of hematopoietic cells. However, in chimeric mice, TEL Ϫ/Ϫ embryonic stem cells contributed to fetal liver hematopoiesis but not to bone marrow-derived hematopoiesis and were unable to colonize the stromal microenvironment (72) . This phenotype was hypothesized to reflect defects in cell adhesion or in pathways responsive to cell adhesion (72) .
Matrix metalloproteinases (MMPs) are a family of secreted, zinc-dependent proteinases that degrade various components of the extracellular matrix (ECM). MMPs are required for cell migration, ECM organization, tissue remodeling, and tumor cell invasion (2) . Cross talk between the signal transduction pathways that are regulated by cell-cell and cell-ECM adhesion may lead to coordinate regulation of these pathways (9, 17, 30, 37, 40, 47, 48, 60, 76) . Consequently, alterations in MMP expression may affect cell-cell interactions as well as cell-ECM adhesion. MMPs are also linked to cell growth. The expression of MMPs is induced by growth factors, and the promoters of the MMP genes contain Ras-responsive elements, which contain binding sites for the ETS family of transcription factors and AP-1 (3, 16, 49, 55) . Moreover, MMP expression may directly contribute to tumor development. For example, expression of stromelysin-1 (MMP-3) in transgenic mice promoted spontaneous premalignant cellular changes and stimulated oncogenic transformation in mammary glands (65) .
We present evidence showing that the TEL transcriptional repressor affects cell growth and causes cell aggregation. TEL inhibited the growth of Ras-transformed cells both in soft agar and in normal cultures. Expression of TEL in Ras-transformed NIH 3T3 cells resulted in a pronounced aggregation of these cells. The aggregation phenotype coincided with a reduction in the expression of the Ras-responsive gene stromelysin-1 (MMP-3). TEL-mediated repression of stromelysin-1 may be critical for the aggregation phenotype because an MMP-specific chemical inhibitor produced a similar phenotype. Finally, MMPs are required for tumor invasion, and we demonstrated that TEL inhibits tumor invasion. These results add biological support for the role of TEL as a tumor suppressor.
MATERIALS AND METHODS
Plasmids. The pBabePuro and pCMVTEL constructs have been described elsewhere (32, 46) . pCMVTEL⌬ETS was made by replacing nucleotides 1143 to 1179 (25) with a BamHI restriction site. The C-terminal BamHI-SalI fragment was amplified using standard PCR techniques, sequenced for verification, and reinserted into BamHI-SalI-cleaved pCMVTEL. This mutation deletes amino acids 373 to 385, which corresponds to the ␣2 helix in the ETS DNA-binding domain as described previously (52) . The TEL and TEL⌬ETS cDNAs were inserted into pBabePuro as EcoRI-SalI fragments. The rat stromelysin-1 reporter from pG7-754TR CAT (43) was inserted into the pGL2 Luciferase vector (Promega) as an Acc65I-BglII fragment. The deletion mutants of the stromelysin-1 promoter were made as follows. pTR334 was made by truncating pGL2-754TR at the unique BsrGI site. pTR182 and pTR127 were made by PCR using oligonucleotides starting at residue Ϫ182 or Ϫ127 (5Ј-TAGGTACCCACCATT CGCTTTGCAAA-3Ј or 5Ј-CATGAGCTCTCACTCTTCTGATTT-3Ј with 5Ј-G CAGATCTCGAGCTAGCACGCGTAAG-3Ј). The fragment was then cloned into the pGL2 vector. pTR89 was made by truncating pGL2-754TR at the unique BstXI site. pTR⌬EBS was made by cutting out the BsrGI-BstXI fragment from pGL2-754TR.
Gel mobility shift assay. Conditions for the gel shift assay were basically as described previously (70) . Proteins and radiolabeled probes were incubated in 10 l of buffer (25 mM HEPES [pH 7.9], 50 mM KCl, 5% glycerol, 0.5 mg of bovine serum albumin per ml, 5 M zinc sulfate, 0.5 mM dithiothreitol) for 30 min at room temperature and then loaded onto an 8% polyacrylamide gel prepared with Tris-glycine buffer. Poly(dI-dC) was used at 500 ng/ml as a nonspecific competitor. Glutathione S-transferase (GST) and GST-TEL fusion proteins were purified with glutathione-Sepharose 4B beads (Pharmacia). Doublestranded consensus ETS factor binding-site oligonucleotides used for the gel shift assay were (sense strand) 5Ј-AATTCATAAACAGGAAGTGGCTT-3Ј (wild type) and 5Ј-AATTCATAAACACTGAGTGGCTT-3Ј (mutant). Oligonucleotides from the stromelysin-1 promoter were as follows: Ϫ213 to Ϫ183, 5Ј-C TAAGGCAGGAAGCATTTCCTGGAGATTAA-3Ј (wild type) and 5Ј-CTAA GGCACTGAGCATTGACTGTCGATTAA-3Ј (mutant); Ϫ111 to Ϫ88, 5Ј-TA ATTTTTGGAAATGGTCCCATTT-3Ј; and Ϫ93 to Ϫ74, 5Ј-CCATTTGGATG GAAGCAATT-3Ј. For the mutant oligonucleotides from the stromelysin-1 promoter, the GGA sequences were changed to TCG in each case.
Cell culture, transfection, retroviral infection, RNA analysis, and cell fractionation. NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; BioWhittaker) supplemented with 10% calf serum (BioWhittaker), 2 mM L-glutamine (BioWhittaker), and 10 g of gentamicin (Sigma) per ml. v-Harvey Ras-transformed NIH 3T3 cells were the generous gift of Stephen J. Brandt.
Retroviral packaging NX cells were maintained in DMEM containing 10% fetal calf serum, 2 mM L-glutamine, and 10 g of gentamicin per ml. Plates (10% confluent) were transfected for 6 to 8 h with 25 l of Lipofectamine reagent (Gibco) and 5 g of the pBabePuro retroviral vectors. The medium was replaced 24 h later, and virus-containing supernatants were harvested at 60 h. Supernatants were filtered through a 0.45-m-pore-size acrodisk (VWR) and added to a plate of NIH 3T3 cells (10% confluent). Ras-expressing cells were infected with retrovirus to eliminate clonal variations. Infected cells were split 1:10 48 h later and selected for 72 h with 1 g of puromycin (Sigma) per ml. Based on the minimal cell death observed upon selection, we concluded that more than 90% of the cells were infected. The cells were used within the first 10 passages after infection, with the critical experiments being performed within the first few passages. However, we observed the phenotypes (e.g., morphology and soft agar) immediately, and they did not change with cell passage. In addition, we used at least five independent batches of retrovirus and obtained similar results. The expressed proteins were detected by immunoblot analysis as described previously (42) . stromelysin-1 mRNA was detected by RNA blot analysis as described previously (1) . Affymetrix gene chip analysis was performed by the Duke University gene analysis core using poly(A) ϩ mRNA from NIH 3T3 cells expressing Ras or Ras plus TEL.
Cell photographs were recorded using a Zeiss Axiophot microscope with a Leaf Lumina digital camera (magnification, ϫ62.5). Images were recorded as TIFF files in Adobe Photoshop. The images were captured with the camera in either the forward or back position, which yielded subtle differences in magnification.
For cell fractionation, cell pellets were resuspended in Iso-Hi buffer (10 mM Tris-HCl [pH 8.4 ], 140 mM NaCl, 1.5 mM MgCl 2 , complete protease inhibitor [Roche], 1 mM EDTA) containing 0.5% NP-40. After 5 min on ice, the nuclei were collected by centrifugation at 2,000 rpm for 5 min in a Beckman GS-6R. Nuclei were reextracted to ensure purity. Equal proportions of the supernatant (cytoplasmic) and nuclear fractions were analyzed by immunoblot analysis with mSin3A, TEL C-terminal, and Ras antisera.
Transcription assays. Cells and supernatants were harvested 44 to 48 h posttransfection. The cells were washed twice with phosphate-buffered saline and lysed in 100 to 200 l of reporter lysis buffer (Promega). Aliquots (10 to 80 l) were assayed for luciferase activity using the luciferase reagent assay (Promega) as specified by the manufacturer. Cytomegalovirus immediate early (CMV)-SEAP (secreted alkaline phosphatase) plasmids were included as internal controls for transfection efficiency (32, 78) . SEAP activity was quantitated as described previously (5), except that the incubations were performed at room temperature. Luciferase activities were then normalized with respect to SEAP activity.
Soft-agar assays. For the bottom agar, 2.5 ml of 1.6% agarose was diluted with 2.5 ml of 2ϫ medium (2ϫ DMEM, 20% calf serum, 4 mM L-glutamine, 20 g of gentamicin per ml, 2 g of puromycin per ml). A 4-ml volume of bottom agar was plated in a 60-mm tissue culture dish and allowed to harden. Cells were trypsinized and resuspended at 1.5 ϫ 10 5 cells/ml in normal medium. The top agar cell suspensions were composed of 300 l of cell suspension, 3.6 ml of 2ϫ medium, and 2.4 ml of 0.75% agarose. Aliquots (2 ml) of this mixture were overlaid on each of two dishes containing bottom agar. The final plating concentration was 1,500 cells per dish.
Matrigel invasion assay. Biocoat Matrigel invasion chambers (Becton Dickinson) were used to assess the invasiveness of TEL-infected NIH 3T3 cells as described previously (8) . Briefly, 5 ϫ 10 4 cells were resuspended in 100 l of serum-free DMEM containing 0.2% bovine serum albumin and added to the cell culture inserts of the invasion chambers. A chemoattractant, 5 g of human fibronectin (Gibco-BRL) per ml, was added to the lower wells. The cells were incubated at 37°C and allowed to invade through the matrix and the pores (8 m) of the attached lower membrane for 48 h. The filters were fixed by immersion in 1% glutaraldehyde and stained with 0.2% crystal violet. The upper surface of the membrane was cleaned with a cotton swab to remove all noninvasive cells. The stained, invasive cells were then photographed using a digital camera.
Mouse tumor formation assays. A single-cell suspension of 5 ϫ 10 4 cells in phosphate-buffered saline was injected subcutaneously into the right lateral flank of 7-week-old athymic female nude (nu/nu) mice (Harlan Sprague-Dawley). The mice were housed in microisolator cages, given food and water ad libitum, and handled in a sterile laminar-flow hood. Tumor sizes were measured every 3 days using Vernier calipers along two perpendicular axes. The mice were sacrificed after 14 days. Primary tumors were excised, fixed overnight in 4% paraformaldehyde in PBS, and stored in 70% ethanol at 4°C. For histologic testing, the tumors were embedded in paraffin and 5-m sections were stained with hematoxylin and eosin. Statistical comparison was performed using an analysis of variance followed by a one-tailed t test.
RESULTS
TEL regulates cell growth. Based on genetic evidence from various cancers, TEL is postulated to be a tumor suppressor in both leukemias and solid tumors (12, 54, 64) . Because oncogenic ETS factors are downstream effectors of Ras-signaling pathways (73, 80) , we tested whether TEL could directly inhibit the growth of Ras-transformed cells. To express TEL but avoid nonspecific effects of high-level overexpression of ETS domain-containing proteins and clonal variation, we infected normal and Ras-transformed NIH 3T3 cells with recombinant retroviruses expressing TEL. For each assay in this study, several different infected-cell populations were used, to reduce the possibility that the results were affected by viral integration site effects. As controls, we tested TEL mutants lacking the N-terminal pointed domain (⌬122 and ⌬P) or containing a small deletion in the ETS domain (TEL⌬ETS) for their ability to inhibit Ras-dependent growth. Immunoblot analysis using a C-terminal TEL antibody confirmed that the mutant proteins were expressed at similar levels (Fig. 1A) . To ensure that the mutant proteins were appropriately transported into the nucleus, we performed cell fractionation experiments. Compared to nuclear (mSin3A) and cytoplasmic (Ras) controls, the majority of the proteins expressed for each mutant were found in the nuclear fractions (Fig. 1B) .
One hallmark of the transformed phenotype is the ability of cells to grow in semisolid medium (56) . Ras-transformed NIH 3T3 cells grew efficiently in soft agar (Fig. 1C) . TEL expression inhibited the ability of Ras-transformed NIH 3T3 cells to grow in an anchorage-independent manner in these assays (Fig. 1C) . This appeared to be due to slower growth, since more colonies became apparent with longer culture times. Deletion of an mSin3-binding domain of TEL, either with a specific internal deletion (⌬P) or by truncation of the N-terminal 122 amino acids, ablated TEL-mediated growth inhibition (Fig. 1C) . Thus, simple overexpression of the TEL DNA-binding domain did not inhibit growth, as observed for ETS-2 (21, 34, 39, 75) . As a further control, we expressed a TEL mutant with a 12-amino-acid deletion within the DNA-binding domain. Unexpectedly, the TEL⌬ETS mutant cooperated with Ras to stimulate growth in soft agar (Fig. 1C) . Because TEL forms homodimers (35, 44) , it is possible that this mutant acts as an inhibitory protein to block endogenous TEL functions. In addition, TEL inhibited the growth of Ras-transformed Rat 1A cells in soft agar (data not shown).
To determine whether TEL could also influence anchoragedependent cell growth, the growth rates of normally cultured cells were determined. TEL did not affect the growth of control NIH 3T3 cells in culture ( Fig. 2A) . However, TEL did slow the growth of Ras-transformed NIH 3T3 cells (Fig. 2B) . As observed in the soft-agar colony assays, TEL⌬ETS cooperated with Ras to cause Ras-expressing cells to grow faster (Fig. 2B) . Although TEL slowed the growth of Ras-transformed cells, there were no signs of apoptosis under normal growth conditions, as determined by morphology or by propidium iodide staining of DNA (data not shown). Also, TEL expression did not dramatically disrupt a specific cell cycle phase as judged by DNA content analysis (data not shown). However, it is possible that the TEL-expressing cells were cycling more slowly but with a proportional lengthening of each phase of the cell cycle.
TEL causes Ras-transformed NIH 3T3 cells to grow as aggregates. In culturing the TEL-expressing cells, it was readily apparent that TEL was affecting the morphology of these cells. At lower densities (i.e., subconfluent growth), Ras-transformed NIH 3T3 cells grew as monolayers (Fig. 3) . TEL did not appear to have any morphological effect on wild-type NIH 3T3 cells (data not shown). By contrast, enforced expression of TEL in Ras-transformed NIH 3T3 cells resulted in an aggregation of these cells under subconfluent conditions (Fig. 3) . As Ras-plus TEL-expressing (Fig. 3 , RasϩTEL) cells continued to grow, most of them piled up rather than spread over the plate. Distinct lanes of cells could also be seen bridging the large clusters of cells (Fig. 3, RasϩTEL LP) . In many cases, these connecting strands consisted of a string of single cells oriented end to end. With extended culturing times, the aggregates grew into large "spheroids" that remained attached to the plate only at the initial point of cell aggregation (data not shown). Unlike control Ras-transformed cells, Ras-plus TEL-expressing cells did not fill the culture dish and did not form transformed "foci" (data not shown). This effect was specific to wild-type TEL, since deletion of the pointed domain or the small deletion in the DNA-binding domain of TEL abolished the phenotype (Fig. 3) .
TEL represses transcription of the stromelysin-1 gene. The phenotype caused by TEL overexpression could be due to alterations in cell-cell or cell-ECM adhesion or to a disruption of cell migration due to changes in the signaling pathways that regulate these processes. Because of the large number of genes involved in these processes that could be directly or indirectly affected by TEL, we performed microarray analysis to define changes in gene expression. RNA extracted from NIH 3T3 cells expressing Ras and from cells expressing Ras plus TEL were compared using Affymetrix gene chip arrays. However, of the nearly 50 genes whose expression was significantly altered, none are directly involved in cell adhesion or migration (data not shown). Because microarray analysis may miss changes in gene expression when genes are expressed at low levels, we asked whether genes that are involved in cell adhesion and that are regulated by Ras and oncogenic ETS factors were repressed by TEL (73) . MMPs are stimulated by Ras through the activation of ETS and AP-1 factors and repressed by negatively acting ETS factors such as Erg (15, 16, 29, 33, 59, 80) . RNA blot analysis indicated that the levels of the MMPs expressed in NIH 3T3 cells, including MMP1, MMP7, and MMP9, were low in these cells and were not affected by TEL (data not shown). While the levels of stromelysin-1 (MMP3) mRNA were also low in control NIH 3T3 cells, these levels were further suppressed by expression of TEL (Fig. 4A, middle panel) . As expected, expression of oncogenic Ras increased stromelysin-1 mRNA levels (Fig. 4A) . However, coexpression of TEL with Ras reduced the amounts of stromelysin-1 mRNA expressed, whereas TEL mutants that lack an mSin3A binding site failed to repress stromelysin-1 (Fig. 4A) . Consistent with the ability of the TEL⌬ETS mutant to cooperate with Ras to stimulate growth, this mutant cooperated with Ras to increase the amount of stromelysin-1 transcript (Fig. 4A) . Thus, TEL regulates the level of stromelysin-1 mRNA.
To determine whether TEL directly represses the stromelysin-1 promoter, we tested whether TEL could repress expression from a plasmid containing stromelysin-1 regulatory sequences linked to a luciferase reporter gene. As little as 20 ng of TEL-expressing plasmid repressed transcription from the rat stromelysin-1 promoter by more than 15-fold in NIH 3T3 cells (Fig. 4B) . This inhibition was specific, since TEL had no effect on the CMV promoter used as an internal control in these experiments. TEL also failed to repress the ETS factorregulated multidrug resistance gene 1 (MDR-1) promoter (reference 41 and data not shown). In addition, mutations of an mSin3-binding domain (⌬122 and ⌬P) or the DNA-binding domain (TEL⌬ETS) impaired TEL-mediated repression (Fig.  4B, left panel) . However, at 10-fold-higher levels of input TEL⌬P expression plasmid, we did observe two-to threefold repression, suggesting competition for DNA-binding sites with endogenous ETS factors (data not shown). When these experiments were repeated in Ras-expressing cells, the basal levels of expression from the stromelysin-1 promoter were higher (data not shown) and TEL-mediated repression was even more dramatic (Fig. 4B, right panel) .
To define the sequences in the stromelysin-1 promoter that are required for TEL-mediated repression, a deletion analysis was performed (Fig. 5A) . Deletion of over 400 bp upstream of a previously mapped ETS factor-binding site (3, 10, 11, 16) had no effect on repression, since the Ϫ334 construct was repressed by over 15-fold ( Fig. 5A and B) . However, deletion to nucleotide Ϫ182, removing the known ETS-binding site, reduced repression to only five-to sixfold (Fig. 5B, TR182 ), indicating that these sequences contributed to TEL-mediated repression. TEL-mediated repression was significantly impaired by deletion to residue Ϫ89 (Fig. 5B, TR89 ). In addition, an internal deletion of sequences from Ϫ334 to Ϫ89 was only marginally responsive to repression by TEL (Fig. 5B, TR⌬EBS) . Although both of these latter deletions reduced the basal expression from the promoter, each promoter was still active, thus allowing us to determine the effects of TEL.
Within the region from Ϫ182 to Ϫ89, there are two putative ETS factor-binding sites at Ϫ103 and Ϫ95 (labeled TBS in Fig.  5A ). Therefore, we deleted sequences upstream of residue Ϫ127 to further isolate the second TEL-responsive sequence. The Ϫ127 promoter was nearly as active as the full-length Ϫ754 promoter, and it was repressed five-to sixfold by TEL expression (Fig. 5B, right panel) . Once again, the Ϫ89 promoter was only weakly inhibited by TEL. Thus, two regions of the stromelysin-1 promoter that contain putative ETS factorbinding sites are responsive to TEL.
To determine whether TEL could directly interact with the TEL-responsive sites in the stromelysin-1 promoter, we asked if TEL could bind these sequences in gel mobility shift assays. A GST-TEL DNA-binding domain fusion protein formed a specific complex with an oligonucleotide encompassing the two ETS factor-binding sites (GGAA at residue Ϫ103 and TCC at residue Ϫ95; the probe contains residues Ϫ111 to Ϫ88 [Fig.  5C] ). This complex was competed by oligonucleotides containing a wild-type but not a mutant consensus ETS factor-binding site that TEL recognizes (52, 53, 77) (Fig. 5C ). Wild-type double-stranded oligonucleotides containing the known ETSbinding sites from the stromelysin-1 promoter (at nucleotides Ϫ205 and Ϫ196) also competed for TEL binding, whereas oligonucleotides containing mutations in the GGA sequences (Fig. 5C , lanes Ϫ205 W and Ϫ205 M). Although the TR89 promoter was slightly repressed at higher levels of input TEL expression plasmid (Fig. 5B, right panel) , the two GGA putative ETS factor-binding sites that remain in this promoter failed to compete for TEL binding (nucleotides Ϫ93 to Ϫ74, labeled Ϫ93 in Fig. 5C ). However, we cannot rule out the possibility that TEL binds these sequences weakly to mediate the reduction in expression observed in Fig. 5B . Therefore, TEL can bind at least two sites in the stromelysin-1 promoter.
In several of the assays described above, the expression of TEL⌬ETS had the opposite effect to the expression of TEL. Because NIH 3T3 cells express endogenous TEL, TEL⌬ETS might act to inhibit endogenous TEL activity or might sequester or titrate a TEL cofactor. However, in these transientexpression assays, the ratio of reporter plasmid to endogenous TEL is likely to be too high for the endogenous TEL to repress transcription and thus allow TEL⌬ETS to "activate" transcription by blocking its action. Consequently, we asked whether TEL⌬ETS could inhibit TEL function when TEL was expressed exogenously in the transcription assays (Fig. 6 ). An equimolar amount of TEL⌬ETS plasmid was sufficient to block TEL-mediated repression, but the mutant did not further activate transcription. Taken together with the biological data ( Fig. 1 to 3) , these results suggest that TEL⌬ETS can act as an inhibitor of TEL function.
An MMP inhibitor yields the same phenotype as TEL expression. Although we thought it unlikely that a single target gene could result in the observed TEL-induced aggregation phenotype, MMPs are critical regulators of cell adhesion and metastasis (14) . Therefore, we used a specific MMP inhibitor, BB-94 (67), to determine whether inhibition of MMPs is important for TEL-mediated cellular aggregation. BB-94 (2 M) was added to the culture medium at the time when the cells were plated, and the cells were allowed to grow for 3 days. BB-94 had no effect on NIH 3T3 morphology (data not shown). By contrast, when added to the culture medium of Ras-transformed NIH 3T3 cells, BB-94 caused the cells to grow in clusters (Fig. 7) , with lanes of cells extending from one cluster to another. This morphology was similar to that observed when TEL was expressed (Fig. 3) .
TEL inhibits Ras-dependent tumor cell invasion. MMPs are critical regulators of cell migration and adhesion. For tumor growth, MMPs are required for angiogenesis and for invasion of surrounding tissue (other than adipose tissue). Therefore, we asked whether TEL expression in Ras-transformed cells could inhibit tumor cell invasion in vitro and in vivo. First, we compared the ability of cells to invade through a reconstituted three-dimensional basement membrane gel (Matrigel) (45) . Control NIH 3T3 cells or TEL-expressing cells invaded the reconstituted matrix only poorly (Fig. 8 upper panel) . Cells expressing oncogenic Ras or cells expressing Ras and TEL⌬ETS, TEL⌬P, or TEL⌬122 invaded through and adhered to the underside of the polycarbonate filter (the invading cells are indicated as dark regions in these stained cultures in Fig. 8 ). By contrast, when TEL was coexpressed with Ras, it inhibited the ability of Ras-transformed cells to invade the three-dimensional matrix (Fig. 8) .
Based on these in vitro results, we injected Ras-expressing NIH 3T3 cells and Ras-plus TEL-expressing cells into nude mice to determine if TEL could inhibit tumor invasion in vivo. The Ras-transformed cells formed tumors readily, and nearly every tumor invaded the surrounding muscle tissue (Table 1) , as determined by gross morphology and by histologic analysis (data not shown). In general, the Ras-plus TEL-expressing cells formed somewhat smaller tumors (Table 1) . However, when tumors of similar size were compared, the TEL-expressing tumors failed to invade the surrounding muscle. At necropsy, three of the TEL-expressing tumors showed the first signs of invasion and were scored as partially positive (Table  1 ). This small number of partially invading tumors could be due to our use of populations of cells that express different amounts of TEL rather than using single-cell clones expressing only large amounts of TEL. However, we conclude that TEL inhibits Ras-mediated tumor cell invasion in vitro and in vivo.
DISCUSSION
Loss of heterozygosity in tumor samples suggests that TEL acts as a tumor suppressor in both leukemias and solid tumors. We have provided biochemical and biological evidence that supports this hypothesis. Expression of TEL inhibited the growth of Ras-transformed cells in soft agar and slowed their growth in normal cultures ( Fig. 1 and 2 ). The ability of TEL to induce cell aggregation suggested that TEL-mediated growth inhibition may be due to alterations in cell adhesion (Fig. 3) . Analysis of stromelysin-1 mRNA levels and the ability of TEL to regulate the stromelysin-1 promoter suggested that TEL acted as a transcriptional repressor to regulate MMP levels. The aggregation phenotype appeared to be partially due to the repression of stromelysin-1 because an MMP inhibitor also caused these cells to grow as aggregates (although the phenotype was not identical to that of TEL-expressing cells [compare Fig. 2 and 7] ). Finally, TEL was shown to inhibit tumor invasion. Therefore, we propose that at least a portion of the action of TEL as a tumor suppressor is to regulate cell growth and tumor cell invasion by repressing target genes such as stromelysin-1.
The repression of both the stromelysin-1 promoter and the endogenous gene suggests that stromelysin-1 is a direct target of TEL-mediated repression. TEL binds a canonical ETS factor-binding site (52, 77) , and it also binds the previously identified consensus ETS-binding site and at least one other site in the stromelysin-1 promoter (Fig. 5) . Our promoter analysis identified two regions containing TEL-binding sites as being important for TEL-mediated repression. Although a link between modulation of stromelysin-1 transcription and Ras-dependent transformation has been established by expressing wild-type Ets-2 or dominant inhibitory mutants of ETS factors (21, 34, 39, 75) , the morphological phenotype associated with TEL expression is distinct. Although the morphological effects of an MMP inhibitor are similar to the effects observed with TEL, TEL probably represses the transcription of other genes involved with growth control.
When an mSin3-binding domain of TEL was deleted, TEL Given that these TEL mutants retain the ETS domain, the biological effects of TEL are due to active repression and not competition for DNA binding with endogenous ETS factors. This is in contrast to the effects of a dominant inhibitor of ETS-2 or the expression of isolated ETS factor-binding domains, which competed for ETS factor-binding sites to inhibit Ras-dependent transformation (21, 34, 39, 75) . Interestingly, the TEL mutants lacking an mSin3A-binding motif retain a domain capable of interacting with the SMRT corepressor (13) . However, in transcription assays, the mSin3A-binding mutant failed to repress transcription (Fig. 4) , suggesting that multiple corepressor contacts are required for TEL-mediated repression. Although the TEL⌬ETS mutant was designed to be a nonfunctional protein, its overexpression had some physiological consequences. When expressed alone, TEL⌬ETS had little or no effect on cell aggregation, cell growth, or transcriptional regulation of stromelysin-1. However, in conjunction with Ras, TEL⌬ETS stimulated cell growth both in exponentially growing cultures and in soft-agar assays. TEL⌬ETS also cooperated with oncogenic Ras to activate stromelysin-1 expression. The effects of this mutant on cell growth but not cell adhesion suggest that TEL also regulates growth independently of its effects on cell adhesion. We will need to define other TEL target genes to fully understand how TEL regulates these complex cell phenotypes.
In chimeric mice derived using TEL Ϫ/Ϫ embryonic stem cells, the TEL-null cells failed to contribute to the developing bone marrow, possibly due to a defect in stem cell migration or adhesion (72) . In NIH 3T3 cells, TEL altered the morphology of the cells, possibly by affecting cell adhesion ( Fig. 3 and 7) . The results obtained with these two experimental systems suggest that the regulation of stromelysin-1 levels by TEL may be important during development. In addition, TEL null mice die in utero at E10.5 due to defects in angiogenesis and MMPs are critical for the tissue remodeling required for angiogenesis (6, 14) . Tumors formed by injecting Ras-plus TEL-expressing cells into nude mice (Table 1) appeared to have less vasculature than did tumors derived from Ras-transformed cells, but this was difficult to quantitate (data not shown). Further work must be performed to establish a direct role for TEL in regulating angiogenesis.
There are several precedents for tumor suppressors that FIG. 7 . An MMP inhibitor produces a phenotype similar to TEL expression. Ras-transformed NIH 3T3 cells were cultured in the presence or absence of BB-94, a specific MMP inhibitor (67) . Cells were grown for 72 h and photographed as described in Materials and Methods.
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regulate cell adhesion. Perhaps the best characterized is Ecadherin. E-cadherin mediates cell-cell interactions and is frequently deleted in metastatic tumors (4, 22, 69) . In fact, altering the expression of stromelysin-1 changed the proteolytic cleavage of E-cadherin (40) . The observation that TEL can inhibit tumor invasion ( Fig. 8 and Table 1 ) may suggest that TEL acts at a late stage of tumor development and that its loss may be associated with metastasis. In at least one case, loss of TEL was a late event in the progression of a t(12;21)-containing leukemia (36) . For leukemogenesis, the ability of immature hematopoietic progenitors to survive in the absence of stromal cell contacts is critical (7, 68) . It is possible that loss of TEL may promote leukemogenesis by affecting cell growth and/or by altering cell adhesion. Future investigations will be necessary to identify additional targets of TEL that may directly or indirectly affect cell adhesion and growth. 
